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EDITORIAL
Immunosuppression for diabetic glomerular disease?
In this issue of Kidney International, Utimura et al [1] glomerular macrophage number increases even before
report that mycophenolate mofetil (MMF) prevents glo- proteinuria appears in diabetic rats [5, 6]. This finding
merular injury in diabetic rats. Because treatment for was confirmed by Utimura et al. They found that 2 months
diabetic glomerular injury is imperfect, their report is of diabetes increased the average number of ED-1-posi-
exciting. Those of us trained to classify renal diseases as tive cells per glomerular profile from 1.4  0.1 to 2.6 
“immune” or “non-immune” will also find it surprising. 0.3 and that this increase was prevented by MMF.
How can a drug introduced into nephrology to prevent The finding of an extra macrophage in glomerular
graft rejection limit glomerular injury caused by lack of profiles that otherwise appear normal would, at first
insulin? It should be noted that MMF has previously glance, seem to be a small matter. But diabetic glomeru-
been shown by the same group [2] and others [3] to limit lar injury is a slow process in rats as well as in humans.
glomerular sclerosis in rats subjected to renal ablation. Utimura et al waited 8 months for uninephrectomized
It appears that the same cellular mechanisms participate diabetic rats to develop injury manifested by modest
in “immune” and “non-immune” injury, and that refined albuminuria and segmental lesions in approximately
“immunosuppressive” drugs could ultimately be used to 15% of glomerular profiles. Comparison of experimental
treat a broad spectrum of renal diseases. diabetes and other disease models suggests that glomeru-
The main findings of Utimura et al [1] can be simply lar macrophage number increases with the pace of glo-
stated. Rats were subjected to uninephrectomy and main- merular injury. This raises the question of what brings
tained diabetic for 8 months. MMF largely prevented the macrophages to glomeruli. Circulating monocytes, which
development of albuminuria and segmental glomerular are the precursors of tissue macrophages, are attracted
injury seen in untreated animals. The beneficial effect of to sites of cellular injury independent of any expression
MMF could not be attributed to reduction of glomerular of foreign antigens. This “innate” immune response is
pressure or improvement of glycemic control. Drug lev- thought to be, in evolutionary terms, older than antigen-
els were not measured, but previous studies have shown dependent immune reactions [7]. Once on the scene,
that the dose used by Utimura et al yields levels similar macrophages both facilitate destruction of dangerously
to those observed in humans taking MMF. It should be damaged cells and stimulate cell proliferation and matrix
emphasized that MMF was effective early in the disease production for tissue repair.
course when visible injury was confined to the glomeru- The presence of macrophages thus suggests that dia-
lus. Untreated rats did not exhibit the interstitial infiltrate betic glomerular injury can be divided in two parts. First,
that is regularly associated with sustained heavy protein- endogenous glomerular cells are “stressed” or “injured”
uria. Thus, in the current study, MMF did not prevent by some combination of hemodynamic forces, metabolic
injury by interrupting the common pathway of interstitial changes, and exposure to altered proteins. These stresses
inflammation and fibrosis, which is thought to accelerate do not cause visible structural changes but do lead to
nephron loss in proteinuric glomerular diseases. secondary expression of cytokines and other factors that
Why did MMF protect the glomerulus? One possibility attract monocyte/macrophages. The beneficial effect of
is that diabetic glomerular disease has an inflammatory MMF remains to be explained. Utimura et al incline to
component, represented by glomerular accumulation of the view the MMF limits injury by preventing macro-
macrophages. As Utimura et al point out in their careful phage accumulation. They suggest that macrophage acti-
discussion, evidence that macrophages participate in glo- vation, although undoubtedly advantageous in many set-
merular injury has been steadily growing. Macrophages tings, causes proteinuria and sclerosis in glomeruli. MMF
are found in normal glomeruli and their number in- could certainly help keep macrophages out of injured
creases in disease [4]. Macrophage number increases glomeruli. Mycophenolic acid (MPA), the active metab-
when nephrosis is induced by toxins, indicating that im- olite of MMF, was chosen for drug development because
mune complex deposition is not necessary for macro- it inhibits the inducible isoform of inosine monophos-
phage accumulation. Several studies have shown that phate dehydrogenase on which lymphocytes and mono-
cytes rely to produce guanine [8]. The resultant depletion
of guanosine nucleotides not only inhibits proliferationKey words: mycophenolate mofetil, glomerular injury, albuminuria,
insterstitial inflammation, monocytes, macrophages, diabetes but has other important effects. Of particular note,
depletion of guanosine nucleotides limits surface expres- 2003 by the International Society of Nephrology
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sion of adhesion molecules on monocytes [8]. The re- kind of early glomerular injury that MMF prevented in
rats. In this regard, it would be most interesting to knowsulting impairment of monocyte adhesion at injury sites,
whether glomerular macrophage number increases earlywhich contributes to the efficacy of MMF in preventing
in the course of human diabetes. To determine whethergraft rejection, could explain the finding that MMF pre-
MMF limits diabetic glomerular disease in humans re-vents macrophage accumulation in glomeruli of diabetic
quires a larger effort. But the finding that MMF worksrats.
in rats will certainly motivate new clinical studies.It should be emphasized that the assumption that mac-
rophages are bad for glomeruli remains unproven. As
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